Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Revenue of Omeros Corporation (OMER)
Revenue in 2023 (TTM): $
According to Omeros Corporation's latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Omeros Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-69,779,000 | $-163,610,000 | $-174,920,000 | $-117,813,000 |
| 2022 | $ | $-952,000 | $-159,327,000 | $-182,029,000 | $28.78 M |
| 2021 | $ | $-1,386,000 | $-171,877,000 | $-191,546,000 | $194.24 M |
| 2020 | $73.81 M | $72.91 M | $-109,947,000 | $-150,072,000 | $-138,061,000 |
| 2019 | $111.81 M | $110.94 M | $-61,829,000 | $-84,486,000 | $-106,906,000 |
| 2018 | $29.87 M | $29.36 M | $-110,441,000 | $-139,686,000 | $-126,757,000 |
| 2017 | $64.83 M | $63.75 M | $-42,451,000 | $-53,481,000 | $-53,481,000 |
| 2016 | $41.62 M | $40.21 M | $-53,331,000 | $-66,745,000 | $-66,745,000 |
| 2015 | $13.51 M | $12.47 M | $-70,208,000 | $-75,096,000 | $-75,096,000 |
| 2014 | $539 K | $-26,189,000 | $-70,215,000 | $-73,673,000 | $-73,673,000 |
| 2013 | $1.6 M | $-16,726,000 | $-49,640,000 | $-39,796,000 | $-39,796,000 |
| 2012 | $6.02 M | $6 M | $-36,755,000 | $-38,444,000 | $-38,444,000 |
| 2011 | $4.52 M | $4.52 M | $-27,723,000 | $-26,662,000 | $-28,546,000 |
| 2010 | $2.11 M | $2.11 M | $-32,024,000 | $-27,716,000 | $-29,251,000 |
| 2009 | $1.44 M | $1.44 M | $-22,178,000 | $-18,887,000 | $-21,089,000 |
| 2008 | $1.17 M | $1.17 M | $-23,719,000 | $-23,827,000 | $-23,827,000 |
| 2007 | $1.92 M | $1.92 M | $-24,147,000 | $-23,091,000 | $-23,091,000 |
| 2006 | $200 K | $200 K | $-23,542,000 | $-22,777,000 | $-22,777,000 |